A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada

European Journal of Neurology

Volumn 23, Issue 6, 2016, Pages 1093-1100

  Mckay, K A ^a   Tremlett, H ^a   Zhu, F ^a   Kastrukoff, L ^a   Marrie, R A ^b   Kingwell, E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Clinical research; Databases; Epidemiology; Health services; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

ADULT; ARTICLE; BRITISH COLUMBIA; COHORT ANALYSIS; COMORBIDITY ASSESSMENT; FEMALE; FOLLOW UP; GENDER; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOCIAL STATUS; COMORBIDITY; FACTUAL DATABASE; INCIDENCE; MIDDLE AGED; OUTPATIENT DEPARTMENT; UTILIZATION;

ADULT; BRITISH COLUMBIA; COMORBIDITY; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OUTPATIENT CLINICS, HOSPITAL;

EID: 84961282368     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12990     Document Type: Article

References (37)

1. Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology 2010; 74: 2004-2015.
2. D'Netto MJ, Ward H, Morrison KM, et al. Risk alleles for multiple sclerosis in multiplex families. Neurology 2009; 72: 1984-1988.
3. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-1438.
4. Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Libr 2013; 6: 1-134.
5. Hillert J, Stawiarz L. The Swedish MS registry - clinical support tool and scientific resource. Acta Neurol Scand 2015; 132: 11-19.
6. Leray E, Morrissey SP, Yaouanq J, et al. Long-term survival of patients with multiple sclerosis in west France. Mult Scler 2007; 13: 865-874.
7. Myhr KM, Grytten N, Aarseth JH, et al. The Norwegian Multiple Sclerosis National Competence Centre and National Multiple Sclerosis registry - a resource for clinical practice and research. Acta Neurol Scand 2006; 113: 37-40.
8. Sayao A-L, Devonshire V, Tremlett H. Longitudinal follow-up of benign multiple sclerosis at 20 years. Neurology 2007; 68: 496-500.
9. Kalincik T, Cutter G, Spelman T, et al. Defining reliable disability outcomes in multiple sclerosis. Brain 2015; 138: 3287-3298.
10. Hurwitz BJ. Registry studies of long-term multiple sclerosis outcomes: description of key registries. Neurology 2011; 76: S3-S6.
11. Debouverie M, Laforest L, Van Ganse E, et al. Earlier disability of the patients followed in multiple sclerosis centers compared to outpatients. Mult Scler 2009; 15: 251-257.
12. Marrie RA, Yu BN, Leung S, et al. The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology 2013; 40: 85-92.
13. Marrie RA, Fisk JD, Yu BN, et al. Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol 2013; 13: 1-8.
14. Marrie RA, Fisk JD, Stadnyk KJ, et al. The incidence and prevalence of multiple sclerosis in Nova Scotia, Canada. Can J Neurol Sci 2013; 40: 824-831.
15. Ramagopalan SV, Handel AE, Giovannoni G, et al. Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology 2011; 76: 1410-1414.
16. Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm 2010; 16: 703-712.
17. Handel AE, Jarvis L, Mclaughlin R, et al. The epidemiology of multiple sclerosis in Scotland: inferences from hospital admissions. PLoS One 2011; 6: 1-5.
18. Kingwell E, Zhu F, Marrie RA, et al. High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010). J Neurol 2015; 262: 2352-2363.
19. British Columbia Ministry of Health (2012). Medical Services Plan (MSP) Payment Information File. V2. Population Data BC. Data Extract. MOH (2012). http://www.popdata.bc.ca/data
20. Canadian Institute for Health Information (2012): Discharge Abstract Database (Hospital Separations). V2. Population Data BC. Data Extract. MOH (2012). http://www.popdata.bc.ca/data
21. BC Ministry of Health (2012): PharmaNet. V2. BC Ministry of Health. Data Extract. Data Stewardship Committee (2012). http://www.popdata.bc.ca/data
22. BC Vital Statistics Agency (2012): Vital Statistic Deaths.V2. Population Data BC. Data Extract. BC Vital Statistics Agency (2012). www.popdata.bc.ca/data
23. British Columbia Ministry of Health (2012). Consolidation File (MSP Registration & Premium Billing). V2. Population Data BC. Data Extract. MOH (2012).www.popdatabc.ca/data
24. Wilkins R. PCCF+ Version 5E User's Guide. Automated Geographic Coding based on the Statistics Canada Postal Code Conversion Files, including Postal Codes through March 2009. Catalogue 82F0086-XDB. Stat Canada 2009.
25. Marrie RA, Yu N, Blanchard J, et al. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology 2010; 74: 465-471.
26. Marrie RA, Yu BN, Leung S, et al. Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler 2012; 18: 1310-1319.
27. Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854-864.
28. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC Classification Index with DDDs. 2015.
29. Sketris I, Hick V, Brown M, et al. Multiple sclerosis disease-modifying drug utilization and cost patterns following introduction of a provincially funded program in Nova Scotia Canada 1998-2004. J Appl Ther Res 2011; 8: 65-78.
30. Kobelt G, Lindgren P, Parkin D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional observational study in the UK: EFI - The Economic Research Institute, Stockholm School of Economics 2000. SSE/EFI Working Paper Series in Economics and Finance, No. 398. Available at: http://hdl.handle.net/10419/56229 (accessed 01/12/2015)
31. Multiple Sclerosis International Federation. Atlas of MS 2013: Mapping multiple sclerosis around the world. 2013.
32. Kingwell E, Leung AL, Roger E, et al. Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci 2010; 292: 57-62.
33. Marrie RA, Horwitz R, Cutter G, et al. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 2009; 72: 117-124.
34. Esbjerg S, Keiding N, Koch-Henriksen N. Reporting delay and corrected incidence of multiple sclerosis. Stat Med 1999; 18: 1691-1706.
35. Alexandra P-T, Calderon-Larranaga A, Hancco-Saavedra J, et al. Multimorbidity patterns: a systematic review. J Clin Epidemiol 2014; 67: 254-266.
36. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278-286.
37. Widdifield J, Ivers NM, Young J, et al. Development and validation of an administrative data algorithm to estimate the disease burden and epidemiology of multiple sclerosis in Ontario, Canada. Mult Scler 2015; 21: 1045-1054.